Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Center for Infectious Disease Imaging, NIH Clinical Center, NIH, Bethesda, MD, United States.
Front Immunol. 2024 Oct 31;15:1441945. doi: 10.3389/fimmu.2024.1441945. eCollection 2024.
Tuberculous meningitis (TBM) has considerable mortality and morbidity, and it often presents therapeutic challenges when complicated by paradoxical reactions (PRs). Here, the clinical course of four cases of TBM patients complicated by PRs in a longitudinal TB cohort is described while also providing insights from the larger clinical cohort. Research flow cytometry, biomarker analysis, and drug concentrations were performed on available samples. All participants were initiated on standard antituberculosis therapy (ATT) and enrolled at the onset of PRs (PR group) or 2-4 months after the start of ATT (controls). The four TBM participants highlighted here presented with fevers, headaches, neurological deficits, and fatigue at the initial presentation. Upon diagnosis, all were initiated on rifampin, isoniazid, pyrazinamide, and ethambutol (RHZE) at standard doses and on corticosteroids. The median time to first PR was 37 days with recrudescence of initial TBM signs and symptoms at the time of PR. At the time of referral, all participants had low drug concentrations requiring dose optimization and regimen intensification as well as recrudescent flares upon corticosteroid taper, with one individual developing enlargement of tuberculoma 1 year following completion of ATT. Based on biomarkers and flow cytometry, PRs are characterized by elevated interferon-gamma and ferritin levels in the plasma compared to controls. In the TBM participants, T-cell activation with elevated levels of inflammatory biomarkers in the cerebrospinal fluid (CSF) was seen at the time of PR. These unique and highly detailed TBM cases provide insights into the pathogenesis of PRs, which may assist with future diagnostics and treatment.
结核性脑膜炎(TBM)具有较高的死亡率和发病率,当并发矛盾反应(PR)时,往往会带来治疗上的挑战。本研究描述了纵向结核病队列中 4 例并发 PR 的 TBM 患者的临床过程,并从更大的临床队列中获得了一些见解。对可获得的样本进行了研究流式细胞术、生物标志物分析和药物浓度检测。所有参与者均开始接受标准抗结核治疗(ATT),并在 PR 发病时(PR 组)或 ATT 开始后 2-4 个月(对照组)入组。本文重点介绍的 4 例 TBM 患者在初次就诊时表现为发热、头痛、神经功能缺损和疲劳。诊断后,所有患者均开始接受标准剂量的利福平、异烟肼、吡嗪酰胺和乙胺丁醇(RHZE)和皮质类固醇治疗。首次 PR 的中位时间为 37 天,PR 时出现初始 TBM 体征和症状的复发。在转诊时,所有患者的药物浓度均较低,需要优化剂量和强化方案,皮质类固醇减量时会出现复发加重,其中 1 例在 ATT 完成 1 年后出现结核瘤增大。基于生物标志物和流式细胞术,与对照组相比,PR 患者的血浆中干扰素-γ和铁蛋白水平升高。在 TBM 患者中,PR 时脑脊液(CSF)中 T 细胞激活并伴有炎症生物标志物水平升高。这些独特且高度详细的 TBM 病例为 PR 的发病机制提供了一些见解,可能有助于未来的诊断和治疗。